Bafna Pharmaceuticals Limited

BAFNAPH

INE878I01022

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
86 ^INR	-0.98%		-0.92%	-6.52%

Feb. 12	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India	MT

Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone

December 07, 2023 at 02:35 am EST

Bafna Pharmaceuticals Limited announced that due to torrential rains/impact of "Michaung" cyclone, the Company's manufacturing facilities in Chennai, Tamil Nadu was totally flooded/waterlogged around the facilities and the production activities have been disrupted from December 04, 2023.

Latest news about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India	Dec. 10	MT
Bafna Pharmaceuticals Limited Announces Commercial Production	Dec. 08	CI
Floods Disrupt Bafna Pharmaceuticals' Manufacturing Plant in Chennai, India	Dec. 07	MT
Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone	Dec. 07	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board	23-09-23	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Bafna Pharmaceuticals Limited Approves Board Appointment	23-06-27	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-27	CI
Bafna Pharmaceuticals Limited Announces Appointment Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer	23-04-07	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director	23-01-19	CI

Chart Bafna Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Companyâs subsidiary is Bafna Lifestyles Remedies Limited.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BAFNA PHARMACEUTICALS LIMITED	-6.52%	24.39M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B